# TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

> **NCT02822586** · PHASE1 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 5 (actual)

## Conditions studied

- Mycosis Fungoides
- Sézary Syndrome

## Interventions

- **RADIATION:** TSEB Therapy
- **DRUG:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT02822586
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-19
- **Primary completion:** 2019-04-29
- **Final completion:** 2019-04-29
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02822586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02822586, "TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02822586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*